NEW YORK TIMES CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEW YORK TIMES CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 27, 2020 | $509.36M | Feb 25, 2021 |
| FY2020 | Sep 27, 2020 | $426.90M | Feb 25, 2021 |
| FY2020 | Jun 28, 2020 | $403.75M | Feb 25, 2021 |
| FY2020 | Mar 29, 2020 | $443.64M | Feb 25, 2021 |
| FY2020 | Dec 29, 2019 | $508.36M | Feb 25, 2021 |
| FY2020 | Sep 29, 2019 | $428.50M | Feb 25, 2021 |
| FY2020 | Jun 30, 2019 | $436.26M | Feb 25, 2021 |
| FY2020 | Mar 31, 2019 | $439.06M | Feb 25, 2021 |
| FY2020 | Dec 30, 2018 | $1.75B | Feb 25, 2021 |
| FY2017 | Dec 31, 2017 | $484.13M | Feb 27, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.82B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.59B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.43B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.31B | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $2.07B | Feb 20, 2024 |
| FY2022 | Dec 27, 2020 | $1.78B | Feb 28, 2023 |
| FY2019 | Dec 29, 2019 | $508.36M | Feb 27, 2020 |
| FY2019 | Sep 29, 2019 | $428.50M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $436.26M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $439.06M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.98M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $293.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $232.39M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $173.91M | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $219.97M | Feb 20, 2024 |
| FY2020 | Dec 27, 2020 | $10.01M | Feb 25, 2021 |
| FY2020 | Sep 27, 2020 | $33.58M | Feb 25, 2021 |
| FY2020 | Jun 28, 2020 | $23.66M | Feb 25, 2021 |
| FY2020 | Mar 29, 2020 | $32.85M | Feb 25, 2021 |
| FY2020 | Dec 29, 2019 | $68.21M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $431.56M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $351.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $276.27M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $201.97M | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $268.03M | Feb 20, 2024 |
| FY2020 | Dec 27, 2020 | $80.53M | Feb 25, 2021 |
| FY2020 | Sep 27, 2020 | $39.60M | Feb 25, 2021 |
| FY2020 | Jun 28, 2020 | $28.81M | Feb 25, 2021 |
| FY2020 | Mar 29, 2020 | $27.32M | Feb 25, 2021 |
| FY2020 | Dec 29, 2019 | $77.97M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $264.35M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $248.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $228.80M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $204.19M | Feb 28, 2023 |
| FY2022 | Dec 26, 2021 | $160.87M | Feb 28, 2023 |
| FY2022 | Dec 27, 2020 | $133.38M | Feb 28, 2023 |
| FY2021 | Dec 29, 2019 | $106.42M | Feb 23, 2022 |
| FY2020 | Dec 30, 2018 | $84.10M | Feb 25, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 29, 2019 | $0 | Feb 25, 2021 |
| FY2020 | Dec 30, 2018 | $0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $815.07M | Feb 27, 2020 |
| FY2018 | Dec 25, 2016 | $728.34M | Feb 26, 2019 |
| FY2017 | Dec 27, 2015 | $713.84M | Feb 27, 2018 |
| FY2016 | Dec 28, 2014 | $761.06M | Feb 22, 2017 |
| FY2015 | Dec 29, 2013 | $706.35M | Feb 24, 2016 |
| FY2013 | Mar 31, 2013 | $176.87M | Feb 26, 2014 |
| FY2013 | Dec 30, 2012 | $186.50M | Feb 26, 2014 |
| FY2013 | Sep 23, 2012 | $169.46M | Feb 26, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $584.49M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $410.51M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $360.62M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $150.69M | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $269.10M | Feb 20, 2024 |
| FY2022 | Dec 27, 2020 | $297.93M | Feb 28, 2023 |
| FY2021 | Dec 29, 2019 | $189.90M | Feb 23, 2022 |
| FY2020 | Dec 30, 2018 | $157.12M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $86.71M | Feb 27, 2020 |
| FY2018 | Dec 25, 2016 | $103.88M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.98M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $29.17M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $22.67M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $36.96M | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $34.64M | Feb 20, 2024 |
| FY2022 | Dec 27, 2020 | $34.45M | Feb 28, 2023 |
| FY2021 | Dec 29, 2019 | $45.44M | Feb 23, 2022 |
| FY2020 | Dec 30, 2018 | $77.49M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $84.75M | Feb 27, 2020 |
| FY2018 | Dec 25, 2016 | $30.10M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.00B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.84B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.71B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.53B | Feb 20, 2024 |
| FY2022 | Dec 26, 2021 | $2.56B | Feb 28, 2023 |
| FY2021 | Dec 27, 2020 | $2.31B | Feb 23, 2022 |
| FY2020 | Dec 29, 2019 | $2.09B | Feb 25, 2021 |
| FY2019 | Dec 30, 2018 | $2.20B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.10B | Feb 26, 2019 |
| FY2017 | Dec 25, 2016 | $2.19B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.93B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.76B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.60B | Feb 20, 2024 |
| FY2022 | Dec 26, 2021 | $1.54B | Feb 28, 2023 |
| FY2021 | Dec 27, 2020 | $1.33B | Feb 23, 2022 |
| FY2020 | Dec 29, 2019 | $1.17B | Feb 25, 2021 |
| FY2019 | Dec 30, 2018 | $1.04B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $897.28M | Feb 26, 2019 |
| FY2017 | Dec 25, 2016 | $847.82M | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.21M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $412.17M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $416.10M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $414.05M | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $166.36M | Feb 20, 2024 |
| FY2022 | Dec 27, 2020 | $171.66M | Feb 28, 2023 |
| FY2021 | Dec 29, 2019 | $138.67M | Feb 23, 2022 |
| FY2020 | Dec 30, 2018 | $140.28M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $143.55M | Feb 27, 2020 |
| FY2018 | Dec 25, 2016 | $134.52M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.33B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.12B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.96B | Feb 20, 2024 |
| FY2022 | Dec 26, 2021 | $1.85B | Feb 28, 2023 |
| FY2021 | Dec 27, 2020 | $1.67B | Feb 23, 2022 |
| FY2020 | Dec 29, 2019 | $1.61B | Feb 25, 2021 |
| FY2019 | Dec 30, 2018 | $1.51B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.31B | Feb 26, 2019 |
| FY2017 | Dec 25, 2016 | $1.33B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $199.45M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $289.47M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $221.39M | Feb 20, 2024 |
| FY2022 | Dec 26, 2021 | $319.97M | Feb 28, 2023 |
| FY2021 | Dec 27, 2020 | $286.08M | Feb 23, 2022 |
| FY2020 | Dec 29, 2019 | $230.43M | Feb 25, 2021 |
| FY2019 | Dec 30, 2018 | $241.50M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $182.91M | Feb 26, 2019 |
| FY2017 | Dec 25, 2016 | $100.69M | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | 1 | Feb 20, 2024 |
| FY2020 | Dec 27, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 27, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 28, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 29, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 29, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | 1 | Feb 20, 2024 |
| FY2020 | Dec 27, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 27, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 28, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 29, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 29, 2019 | 0 | Feb 25, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $82.86M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $69.46M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $56.79M | Feb 27, 2025 |
| FY2023 | Dec 26, 2021 | $45.34M | Feb 20, 2024 |
| FY2022 | Dec 27, 2020 | $38.44M | Feb 28, 2023 |
| FY2021 | Dec 29, 2019 | $31.60M | Feb 23, 2022 |
| FY2020 | Dec 30, 2018 | $26.42M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $26.00M | Feb 27, 2020 |
| FY2018 | Dec 25, 2016 | $25.90M | Feb 26, 2019 |